Abstract
Systemic enzymes (wobenzime and wobe-mugos) were approved, that had been prescribed as part of polychemotherapy to 24 patients with malignant lymphomas, who presented with large masses of lymphatic nodes poorly resorbable against the background of polychemotherapy and who were assigned for a high-total dose irradiation, which fact would undoubtedly entail sclerosing of adjacent intact tissues. The use of the enzymes made for the optimum realization of the polychemotherapy effect and permitted avoiding a good many of undesirable side events and complication thereof. The above systemic enzymes are well tolerated by patients; they induce no significant changes in the cellular composition or in blood biochemical indices.
MeSH terms
-
Adjuvants, Immunologic / therapeutic use*
-
Adolescent
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Blood / drug effects
-
Chymotrypsin*
-
Combined Modality Therapy
-
Drug Combinations
-
Drug Evaluation
-
Female
-
Hodgkin Disease / blood
-
Hodgkin Disease / drug therapy
-
Hodgkin Disease / radiotherapy
-
Humans
-
Hydrolases / therapeutic use*
-
Lymphoma / blood
-
Lymphoma / drug therapy*
-
Lymphoma / radiotherapy
-
Male
-
Middle Aged
-
Pancreatic Extracts / therapeutic use*
-
Papain / therapeutic use*
-
Recurrence
-
Rutin / therapeutic use*
-
Thymus Extracts / therapeutic use*
-
Trypsin*
Substances
-
Adjuvants, Immunologic
-
Drug Combinations
-
Pancreatic Extracts
-
Thymus Extracts
-
Rutin
-
chymotrypsin, papain, trypsin drug combination
-
Wobenzym
-
Hydrolases
-
Chymotrypsin
-
Trypsin
-
Papain